Osimertinib is used as a first-line treatment for metastatic non-small cell lung cancer with positive epidermal growth factor receptor mutations based on the results of the FLAURA trial. However, as with any other epidermal growth factor receptor tyrosine kinase inhibitor, resistance also develops for osimertinib. Various genetic aberrations associated with the molecular heterogeneity of cancer cells contribute to osimertinib resistance. It is also important to choose an appropriate subsequent treatment for osimertinib-resistant non-small cell lung cancer. In this overview, we discuss the underlying mechanisms of osimertinib resistance and the efficacy of possible subsequent treatment measures.

根据 FLAURA 试验的结果，奥希替尼被用作表皮生长因子受体阳性突变的转移性非小细胞肺癌的一线治疗。然而，与任何其他表皮生长因子受体酪氨酸激酶抑制剂一样，奥希替尼也会产生耐药性。与癌细胞的分子异质性相关的各种遗传异常导致奥希替尼耐药。为奥希替尼耐药的非小细胞肺癌选择合适的后续治疗也很重要。在本概述中，我们讨论了奥希替尼耐药的潜在机制以及可能的后续治疗措施的功效。